U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H6BFO2
Molecular Weight 151.931
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAVABOROLE

SMILES

OB1OCC2=C1C=CC(F)=C2

InChI

InChIKey=LFQDNHWZDQTITF-UHFFFAOYSA-N
InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2

HIDE SMILES / InChI
Molecular Formula C7H6BFO2
Molecular Weight 151.931
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662369/

Tavaborole is a boron-based pharmaceutical agent indicated for the topical treatment of toenail onychomycosis, a fungal infection of the nail and nail bed due to Trichophyton rubrum or Trichophyton mentagrophytes infection. Tavaborole acts by inhibiting an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS) - Leucyl-tRNA synthetase. Leucyl-tRNA synthetase is an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu). Tavaborole’s low molecular weight (approximately half of most antifungals, such as terbinafine and efinaconazole) permits optimal nail plate penetration, superior to that of existing topical antifungal medications.

Originator

Approval Year

2014
503
Targets

Targets

Primary TargetPharmacologyConditionPotency
ENTREZ Gene ID: 10373871 (leucyl-tRNA synthetase)
1
Target ID: ENTREZ Gene ID: 10373871 (leucyl-tRNA synthetase)
Antagonist
2849
ENTREZ Gene ID: 10373705 (leucyl-tRNA synthetase)
1
Target ID: ENTREZ Gene ID: 10373705 (leucyl-tRNA synthetase)
Antagonist
2849
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8583
KERYDIN

Approved Use

KERYDIN (tavaborole) topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Launch Date

2014
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.9 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf
5 % 1 times / day multiple, topical
dose: 5 %
route of administration: Topical
experiment type: MULTIPLE
co-administered:
TAVABOROLE blood
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
5.2 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf
5 % 1 times / day multiple, topical
dose: 5 %
route of administration: Topical
experiment type: MULTIPLE
co-administered:
TAVABOROLE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
76 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf
5 % 1 times / day multiple, topical
dose: 5 %
route of administration: Topical
experiment type: MULTIPLE
co-administered:
TAVABOROLE blood
Homo sapiens
population: UNHEALTHY
age: ADOLESCENT
sex: UNKNOWN
food status: UNKNOWN
75.8 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204427s006lbl.pdf
5 % 1 times / day multiple, topical
dose: 5 %
route of administration: Topical
experiment type: MULTIPLE
co-administered:
TAVABOROLE blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
28.5 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000ClinPharmR.pdf
5 % 1 times / day multiple, topical
dose: 5 %
route of administration: Topical
experiment type: MULTIPLE
co-administered:
TAVABOROLE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 7.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 7.5 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
unhealthy, 18-65 years
Health Status: unhealthy
Age Group: 18-65 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
Disc. AE: Application site stinging, Pruritus...
Other AEs: Application site irritation, Application site erythema...
AEs leading to
discontinuation/dose reduction:
Application site stinging (grade 2)
Pruritus (grade 2)
Irritation skin (grade 3)
Other AEs:
Application site irritation
Application site erythema
Application site reaction
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Disc. AE: Application site erythema, Application site exfoliation...
AEs leading to
discontinuation/dose reduction:
Application site erythema (grade 2, 0.5%)
Application site exfoliation (grade 2, 0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Disc. AE: Ingrowing nail, Application site pain...
Other AEs: Skin induration...
AEs leading to
discontinuation/dose reduction:
Ingrowing nail (0.5%)
Application site pain (0.5%)
Application site discharge (0.5%)
Application site exfoliation (0.5%)
Application site edema (0.5%)
Edema peripheral (0.5%)
Application site erythema (0.5%)
Erythema (0.5%)
Application site induration (0.5%)
Application site reaction (0.5%)
Skin maceration (0.5%)
Application site pruritus (0.5%)
Pruritus (0.5%)
Other AEs:
Skin induration (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Other AEs: Dermatitis contact...
Other AEs:
Dermatitis contact (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Other AEs: Hypercholesterolaemia, Blood creatinine increased...
Other AEs:
Hypercholesterolaemia (1.01%)
Blood creatinine increased (0.51%)
Blood glucose increased (0.38%)
Blood urea increased (0.38%)
Hyperglycaemia (0.38%)
Hyperlipidaemia (0.38%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Other AEs: Upper respiratory tract infection, Back pain...
Other AEs:
Upper respiratory tract infection (5.44%)
Back pain (3.29%)
Application site exfoliation (2.65%)
Ingrowing nail (2.53%)
Procedural pain (2.53%)
Muscle strain (2.4%)
Arthralgia (2.15%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Application site erythema
7.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 7.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 7.5 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
unhealthy, 18-65 years
Health Status: unhealthy
Age Group: 18-65 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
Application site irritation
7.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 7.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 7.5 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
unhealthy, 18-65 years
Health Status: unhealthy
Age Group: 18-65 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
Application site reaction
7.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 7.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 7.5 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
unhealthy, 18-65 years
Health Status: unhealthy
Age Group: 18-65 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
Application site stinging grade 2
Disc. AE
7.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 7.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 7.5 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
unhealthy, 18-65 years
Health Status: unhealthy
Age Group: 18-65 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
Pruritus grade 2
Disc. AE
7.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 7.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 7.5 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
unhealthy, 18-65 years
Health Status: unhealthy
Age Group: 18-65 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
Irritation skin grade 3
Disc. AE
7.5 % 1 times / day multiple, topical
Highest studied dose
Dose: 7.5 %, 1 times / day
Route: topical
Route: multiple
Dose: 7.5 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
unhealthy, 18-65 years
Health Status: unhealthy
Age Group: 18-65 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/24894552/
https://pubmed.ncbi.nlm.nih.gov/25226015/
https://pubmed.ncbi.nlm.nih.gov/27224843/
Application site erythema grade 2, 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site exfoliation grade 2, 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Skin induration 0.5%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site discharge 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site edema 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site erythema 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site exfoliation 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site induration 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site pain 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site pruritus 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site reaction 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Edema peripheral 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Erythema 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Ingrowing nail 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Pruritus 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Skin maceration 0.5%
Disc. AE
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Dermatitis contact 0.5%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Blood glucose increased 0.38%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Blood urea increased 0.38%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Hyperglycaemia 0.38%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Hyperlipidaemia 0.38%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Blood creatinine increased 0.51%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Hypercholesterolaemia 1.01%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Arthralgia 2.15%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Muscle strain 2.4%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Ingrowing nail 2.53%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Procedural pain 2.53%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Application site exfoliation 2.65%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Back pain 3.29%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Upper respiratory tract infection 5.44%
5 % 1 times / day multiple, topical
Recommended
Dose: 5 %, 1 times / day
Route: topical
Route: multiple
Dose: 5 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
unhealthy, mean age 55 years
Health Status: unhealthy
Age Group: mean age 55 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204427Orig1s000MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946
inducer
440

inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2A6
879

CYP2B6
926

CYP2C8
1057

CYP2C19
2057

CYP2E1
1060

CYP3A4/5
296
CYP3A5
446

CYP2C18
149

CYP2C19
1119

FMO3
77
CYP1A2
832

CYP2B6
669

CYP2C8
198

CYP2C19
329

CYP3A4/5
133
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 unlikely [IC50 >100 uM]
CYP2B6
1160
 unlikely [IC50 >100 uM]
CYP2C19
2141
 unlikely [IC50 >100 uM]
CYP2C8
1117
 unlikely [IC50 >100 uM]
CYP2C9
2497
 unlikely [IC50 >100 uM]
CYP2D6
2546
 unlikely [IC50 >100 uM]
CYP3A4/5
357
 unlikely [IC50 >100 uM]
CYP2A6
911
 unlikely [Inhibition 100 uM]
CYP2E1
1146
 unlikely [Inhibition 100 uM]
CYP1A2
2333
 unlikely
CYP2B6
1160
 unlikely
CYP2C19
2141
 unlikely
CYP2C8
1117
 unlikely
CYP2C9
2497
 unlikely
CYP3A4/5
357
 unlikely
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2C18
149
 yes
CYP2C19
1119
 yes
CYP3A4
1946
 yes
CYP3A5
446
 yes
FMO3
77
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:77942
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:77942
ChemicalBook
CB42454906
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB42454906
MolPort
MolPort-027-845-281
https://www.molport.com/shop/molecule-link/MolPort-027-845-281
ZINC
ZINC000169990691
http://zinc15.docking.org/substances/ZINC000169990691
PubMed

PubMed

TitleDatePubMed
The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
2014-09
Tavaborole: first global approval.
2014-09
Post-transfer editing by a eukaryotic leucyl-tRNA synthetase resistant to the broad-spectrum drug AN2690.
2010-09-01
A genomic glimpse of aminoacyl-tRNA synthetases in malaria parasite Plasmodium falciparum.
2009-12-31
Crystal structures of the human and fungal cytosolic Leucyl-tRNA synthetase editing domains: A structural basis for the rational design of antifungal benzoxaboroles.
2009-07-10
In Vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate.
2007-10
AN-2690, a novel antifungal for the topical treatment of onychomycosis.
2007-08
An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site.
2007-06-22
Recent progress on the topical therapy of onychomycosis.
2007-02
Spotlight on targeting aminoacyl-tRNA synthetases for the treatment of fungal infections.
2006-09-15
Discovery of a new boron-containing antifungal agent, 5-fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the potential treatment of onychomycosis.
2006-07-27
Patents

Patents

07271264
1
08106031
3
20050261277
1
20060234981
3
20070155699
3
20070265226
2

Sample Use Guides

In Vivo Use Guide
Tavaborole 5% topical solution (each milliliter of solution contains 43.5 mg of tavaborole) should be applyed to affected toenails once daily for 48 weeks. It should be applied to the entire toenail surface and under the tip of each toenail being treated (for topical use only and not for oral, ophthalmic, or intravaginal use).
Route of Administration: Topical
In Vitro Use Guide
Tavaborole demonstrated minimum inhibitory concentration (MIC) values ranging from 0.25–2 μg/mL against all fungi tested; addition of 5% keratin powder did not affect the MIC against T rubrum. The minimum fungicidal concentration (MFC) values for tavaborole against T rubrum and T mentagrophytes were 8 and 16 μg/mL, respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:27:57 GMT 2025
Edited
by admin
on Mon Mar 31 18:27:57 GMT 2025
Record UNII
K124A4EUQ3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
tavaborole [INN]
Preferred Name English
TAVABOROLE
DASH   INN   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
Tavaborole [WHO-DD]
Common Name English
TAVABOROLE [VANDF]
Common Name English
TAVABOROLE [MI]
Common Name English
TAVABOROLE [ORANGE BOOK]
Common Name English
TAVABOROLE [USAN]
Common Name English
AN-2690
Code English
AN2690
Code English
SCH-900340
Code English
2,1-BENZOXABOROLE, 5-FLUORO-1,3-DIHYDRO-1-HYDROXY-
Systematic Name English
KERYDIN
Brand Name English
SCH 900340
Code English
5-Fluoro-2,1-benzoxaborol-1(3H)-ol
Systematic Name English
5-FLUORO-1,3-DIHYDRO-1-HYDROXY-2,1-BENZOXABOROLE
Systematic Name English
Classification Tree Code System Code
NDF-RT N0000191279
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
NCI_THESAURUS C28394
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
NCI_THESAURUS C514
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
WHO-ATC D01AE24
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
Code System Code Type Description
DAILYMED
K124A4EUQ3
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
DRUG CENTRAL
4877
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
NDF-RT
N0000008253
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY Boron Compounds [Chemical/Ingredient]
LACTMED
Tavaborole
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
HSDB
8342
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
MERCK INDEX
m11751
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
INN
9425
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
USAN
XX-15
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
DRUG BANK
DB09041
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
CAS
174671-46-6
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
FDA UNII
K124A4EUQ3
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
ChEMBL
CHEMBL443052
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
CHEBI
77942
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
NCI_THESAURUS
C81725
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
SMS_ID
100000174859
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
WIKIPEDIA
Tavaborole
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
RXCUI
1543173
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY RxNorm
EPA CompTox
DTXSID00169888
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
PUBCHEM
11499245
Created by admin on Mon Mar 31 18:27:57 GMT 2025 , Edited by admin on Mon Mar 31 18:27:57 GMT 2025
PRIMARY
Related Record Type Details
TRICHOPHYTON MENTAGROPHYTES
TARGET ORGANISM->INHIBITOR
TRICHOPHYTON RUBRUM
TARGET ORGANISM->INHIBITOR
Related Record Type Details
Structure of 2-HYDROXY-5-FLUOROBENZOIC ACID
METABOLITE -> PARENT
MINOR
PLASMA
Related Record Type Details
Structure of TAVABOROLE
ACTIVE MOIETY
Used to treat toenail infection caused by fungus.
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC SINGLE TOPICAL APPLICATION ON DAY 1

NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966